Abstract Number: 1739 • ACR Convergence 2020
Patients with Early Rheumatoid Arthritis Considered to Have a Favourable Risk Profile and Treated According to a Step-up Strategy Have an Increased Risk of Chronic Analgesic Consumption
Background/Purpose: Pain remains the highest priority for improvement to patients with Rheumatoid Arthritis (RA). Analgesic prescription in RA was historically a stand-alone approach and afterwards…Abstract Number: 0306 • ACR Convergence 2020
Characteristics of Patients with Early Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Background/Purpose: The efficacy of apremilast vs placebo for the treatment of oligoarticular PsA of ≤2 years duration is being investigated in the FOREMOST trial (NCT03747939).…Abstract Number: 0742 • ACR Convergence 2020
Effect of IA OnabotulinumtoxinA and Vanilloids on Substance P and Neurokinin 1 Receptor Expression in the Dorsal Root Ganglia of Mice with Monoarthritis
Background/Purpose: Neurotoxins are increasingly being proposed as analgesics for arthritis pain. Phase II and III clinical trials have shown efficacy but with potential toxicities such…Abstract Number: 1215 • ACR Convergence 2020
Filgotinib Provided Rapid and Sustained Relief of Pain and Fatigue and Improved Health-Related Quality of Life in Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs
Background/Purpose: EULAR guidelines recommend a treat-to-target approach focusing on reducing inflammation to prevent joint damage, physical disability, and mortality.1 However, patients consider reduction in pain…Abstract Number: 1640 • ACR Convergence 2020
Clinically Important Improvement in Osteoarthritis Pain at Week 16 After Subcutaneous Administration of Tanezumab: Pooled Analysis from International Studies
Background/Purpose: Tanezumab is under investigation for the treatment of moderate to severe OA pain. As part of the phase 3 OA program, two randomized, placebo-controlled…Abstract Number: 1854 • ACR Convergence 2020
NGF/TrkA System Regulates Pain and the Pannus Formation: Targeting NGF-TrkA in Psoriatic Arthritis
Background/Purpose: Function of Nerve Growth Factor (NGF) in the nervous system and its regulatory role in pain is well defined. We have shown earlier that…Abstract Number: 0340 • ACR Convergence 2020
Neuropathic Pain Relationship with Comorbidity in Psoriatic Arthritis Patients and Its Influence on Disease Activity
Background/Purpose: In psoriatic arthritis (PsA) peripheral nociceptive pain is characteristic, and is trigger by the activation of the afferent sensory fibers in the inflamed synovial…Abstract Number: 0769 • ACR Convergence 2020
Does the Autoantibody-Response Mature Between Presentation with Arthralgia and Development of Rheumatoid Arthritis? – a Longitudinal Serological Study
Background/Purpose: Auto-antibodies in rheumatoid arthritis (RA) are often present years before disease onset but their mere presence does not seem enough to induce RA. Several…Abstract Number: 1218 • ACR Convergence 2020
Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, Health-related Quality of Life, and Fatigue in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate
Background/Purpose: In the FINCH 1 study, filgotinib (FIL)—an oral, potent, selective JAK1 inhibitor—plus methotrexate (MTX) provided significant improvements in signs and symptoms of rheumatoid arthritis…Abstract Number: 1641 • ACR Convergence 2020
Clinically Important Improvements in Patients with Osteoarthritis Treated with Subcutaneous Tanezumab: Results from a 56-Week Randomized NSAID-Controlled Study
Background/Purpose: Subcutaneous (SC) tanezumab, a monoclonal antibody that inhibits nerve growth factor, was investigated for the relief of signs and symptoms of moderate-severe OA in…Abstract Number: 1900 • ACR Convergence 2020
The Clinical and the Functional Impact of Central Sensitization on Patients with Axial Spondyloarthritis
Background/Purpose: To evaluate the impact of central sensitization (CS) on axial spondyloarthritis (AxSpA) patients’ clinical and functional situation and quality of life.Methods: Subjects with axSpA…Abstract Number: 0373 • ACR Convergence 2020
Medical Cannabis in Ankylosing Spondylitis Following Recreational Legalization: A Prospective Cross-sectional Study
Background/Purpose: Recreational legalization of cannabis has influenced the medical use by patients. When only legal medical access was available in Canada, 4.3% of all rheumatology…Abstract Number: 0811 • ACR Convergence 2020
Long-term Opioid Use in Patients with Rheumatoid Arthritis Treated with Sarilumab
Background/Purpose: Prescription opioids are routinely used in patients with RA. However, use of opioids should be minimized to prevent abuse and addiction. Chronic opioid use…Abstract Number: 1224 • ACR Convergence 2020
Glucocorticoid Reduction in Different Profiles of Patients with Rheumatoid Arthritis and Treatment with Sarilumab
Background/Purpose: Glucocorticoid reduction in different profiles of patients with rheumatoid arthritis and sarilumab treatment. Real clinical practice studies are tasked with providing clinically relevant data…Abstract Number: 1642 • ACR Convergence 2020
Observed Efficacy with Subcutaneous Tanezumab Is Early and Maintained in Patients with Osteoarthritis: Results from a 56-Week Randomized NSAID-Controlled Study
Background/Purpose: Subcutaneous (SC) tanezumab, a monoclonal antibody that inhibits nerve growth factor, was investigated for the relief of signs and symptoms of moderate-severe OA in…
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 37
- Next Page »